Retatrutide vs Semaglutide vs Tirzepatide

This comparison reflects our 2026 reading of the head-to-head trial data. We weigh these three incretin peptides by receptor coverage and reported outcomes, and note where a result comes from an earlier-phase study.

Verdict: Which Wins?

For maximum weight-loss and hepatic-fat research endpoints, retatrutide leads with 24.2% mean body-weight loss (Phase 2), driven by its unique triple GLP-1/GIP/glucagon receptor agonism. For cardiovascular-outcome work, semaglutide wins on the deepest evidence base (SELECT trial); for the largest mature Phase 3 dataset, tirzepatide is the established choice. The single key differentiator is receptor count: retatrutide's third receptor (glucagon) raises the efficacy ceiling but demands slower titration, while semaglutide and tirzepatide trade a lower ceiling for MHRA authorisation and deeper safety data.

Key Takeaways

• Retatrutide is a triple-receptor agonist (GLP-1/GIP/glucagon) showing 24.2% mean body-weight loss at 48 weeks in Phase 2 trials, versus tirzepatide's ~22.5% and semaglutide's ~15%
• Only semaglutide (Wegovy) and tirzepatide (Mounjaro) are MHRA-authorised in the UK; retatrutide remains investigational under Lilly's TRIUMPH Phase 3 programme
• Retatrutide's glucagon arm drives hepatic fat oxidation, explaining reported liver-fat reductions of up to 86%, but requires slower titration than dual or mono-agonists
• Semaglutide carries the deepest cardiovascular evidence base (SELECT trial); tirzepatide offers mature Phase 3 data; retatrutide offers the highest weight-loss ceiling but limited Phase 3 confirmation
• Compound choice depends on research endpoint: weight-loss ceiling favours retatrutide; cardiovascular outcomes favour semaglutide; largest Phase 3 evidence base favours tirzepatide

Last updated: 2026

How the Three Peptides Differ

Semaglutide is a GLP-1 mono-agonist. Tirzepatide is a GLP-1/GIP dual-agonist. Retatrutide is a GLP-1/GIP/glucagon triple-agonist, a structure unique to retatrutide [1][2].

Peak trial weight loss scales with receptor count. Retatrutide reached 24.2% mean body-weight reduction at 12 mg/48 weeks in the Jastreboff et al. Phase 2 trial (NEJM, 2023) [1][3]. Tirzepatide reached ~22.5% at 15 mg/72 weeks in SURMOUNT-1. Semaglutide reached ~14.9% at 2.4 mg/68 weeks in STEP 1.

For a UK researcher, receptor breadth predicts both efficacy and titration complexity. Retatrutide's glucagon arm adds a hepatic fat-oxidation pathway absent from the other two, which is why its titration protocol requires slower step-ups than semaglutide dosing to manage glucagon-driven glycaemic effects.

Summary table

Receptor Mechanisms: GLP-1, GIP, and Glucagon Explained

Each incretin receptor contributes a distinct metabolic output. Semaglutide engages GLP-1 alone. Tirzepatide engages GLP-1 and GIP. Retatrutide engages all three, and that third receptor, glucagon, decouples weight loss from appetite suppression and routes it through hepatic energy expenditure [1][3].

GLP-1 receptor agonism

GLP-1 receptor activation suppresses appetite by slowing gastric emptying, increasing central satiety signalling in the hypothalamus, and triggering glucose-dependent insulin secretion from pancreatic beta cells [1]. This is the entire pharmacological surface of semaglutide. It explains both its ~14.9% peak weight loss in STEP 1 and its dose-limiting nausea profile, gastric-emptying delay is the same pathway that drives upper-GI side effects. Researchers titrating from 0.25 mg upward should consult the semaglutide dosing schedule to manage that trade-off.

GIP receptor agonism

GIP receptor activation potentiates glucose-dependent insulin secretion and appears to attenuate the nausea ceiling seen with pure GLP-1 agonism. This is why tirzepatide tolerates higher functional dosing than semaglutide at equivalent weight-loss endpoints [5]. GIP also modulates adipocyte lipid handling, improving postprandial lipid clearance. The combined GLP-1/GIP signal in tirzepatide is the mechanistic basis for its ~22.5% SURMOUNT-1 result, outperforming semaglutide's STEP 1 figure by roughly 7.6 percentage points.

Glucagon receptor agonism: the differentiator

Glucagon receptor activation increases hepatic fat oxidation and raises resting energy expenditure. This is the mechanism that dual-agonist guides routinely omit when explaining retatrutide's efficacy gap [1][3]. Glucagon agonism was historically avoided in obesity drug design because unopposed glucagon raises hepatic glucose output and risks hyperglycaemia.

Retatrutide mitigates this through balanced triple agonism. The concurrent GLP-1 and GIP arms drive glucose-dependent insulin secretion that offsets glucagon-induced gluconeogenesis, producing net euglycaemia alongside elevated lipolysis (Jastreboff et al., NEJM, 2023) [1]. Secondary 2026 analyses attribute retatrutide's reported hepatic fat reduction of up to 86% to this glucagon arm, though the primary MASLD endpoint paper is [unverified] in this dataset [1].

The practical consequence is a slower required step-up than either mono- or dual-agonist regimens. The retatrutide titration protocol reflects this by extending dose-escalation intervals to let glycaemic counter-regulation stabilise.

Weight-Loss Data Compared: Trial Results Side by Side

Across the three pivotal trials, peak mean body-weight reductions rank retatrutide 12 mg at 24.2% (48 weeks, Phase 2), tirzepatide 15 mg at 22.5% (72 weeks, Phase 3), and semaglutide 2.4 mg at 14.9% (68 weeks, Phase 3) [1][2][5]. The retatrutide figure is the highest reported, but it comes from a shorter Phase 2 study and has not yet been confirmed at Phase 3 scale.

Why these numbers aren't directly comparable

Cross-trial comparison overstates precision. STEP 1, SURMOUNT-1, and the Jastreboff Phase 2 enrolled different populations. BMI thresholds, type 2 diabetes status, and ethnic composition varied. Trial durations differed. Placebo-subtracted versus total-change reporting was inconsistent in secondary summaries. The 48-week retatrutide curve had not plateaued at readout, so the 24.2% figure likely under-represents the 72-week steady state that would match SURMOUNT-1's window [1].

Population matters more than most side-by-side tables acknowledge. SURMOUNT-1 excluded type 2 diabetes. The parallel SURMOUNT-2 cohort with type 2 diabetes lost roughly 6–7 percentage points less on the same dose. That pattern will likely repeat in retatrutide's type 2 diabetes arm once Phase 3 reports.

Evidence maturity is the real differentiator

Semaglutide carries the deepest evidence base. The full STEP 1–8 programme, SUSTAIN cardiovascular data, and several years of NHS real-world prescribing through specialist weight-management services all support it. Practical dose-escalation experience is well-mapped in the how to dose semaglutide guide.

Tirzepatide has completed the SURMOUNT Phase 3 programme and is in routine UK clinical use as Mounjaro. MHRA weight-management label specifics should be checked against the primary record [unverified].

Retatrutide remains investigational. Lilly's TRIUMPH Phase 3 programme is underway, with TRIUMPH-4 identified as a Phase 3 study. No primary completion date is confirmed in the sources reviewed here [2]. Until Phase 3 readouts publish, the 24.2% figure should be treated as a Phase 2 signal rather than a regulatory-grade endpoint. Any procurement decision based on it should account for the slower titration described in the retatrutide titration protocol.

The Glucagon Advantage: Why Retatrutide's Ceiling Is Higher

Retatrutide's higher weight-loss ceiling exists because glucagon receptor agonism adds a second, parallel fat-loss pathway that tirzepatide and semaglutide do not engage. GLP-1 and GIP reduce energy intake by suppressing appetite and slowing gastric emptying. The glucagon arm raises energy expenditure by accelerating hepatic fatty-acid oxidation. These are not redundant mechanisms, they operate on different tissues and different timescales.

The mechanistic chain is specific. Hepatic glucagon receptor activation upregulates carnitine palmitoyltransferase 1 (CPT1), the rate-limiting enzyme that shuttles long-chain fatty acids across the outer mitochondrial membrane for β-oxidation. With more CPT1 capacity, the liver oxidises a greater fraction of incoming free fatty acids rather than re-esterifying them into triglyceride. Two clinical signatures follow: a measurable rise in resting energy expenditure (REE) independent of caloric deficit, and substantial reductions in intrahepatic lipid.

Secondary 2026 summaries describe retatrutide producing liver-fat reductions of up to 86%, attributed mechanistically to the glucagon component, though the underlying MASLD paper is not surfaced in the sources reviewed here [1] [unverified]. Direct human CPT1 biomarker data from a 2023–2026 cohort is likewise [unverified] in this dataset. The CPT1 mechanism is inferred from preclinical work and the foundational Finan et al. (2015) GLP-1/glucagon co-agonist REE data, which remains the mechanistic anchor for every triagonist programme that followed [unverified].

The clinical expression shows up in Jastreboff et al. (NEJM 2023), where retatrutide 12 mg produced 24.2% mean body-weight loss at 48 weeks without a plateau [1]. Tirzepatide's SURMOUNT-1 curve flattened earlier at a lower ceiling, consistent with a mechanism that primarily caps intake rather than also raising expenditure.

The trade-off is hyperglycaemia risk. Glucagon agonism, in isolation, raises hepatic glucose output. In retatrutide, the GLP-1 arm's insulinotropic effect offsets this, but only if the glucagon component is introduced gradually relative to GLP-1/GIP exposure. That is why retatrutide titration is slower and more granular than tirzepatide's, and why dose-skipping carries different consequences. The retatrutide titration protocol covers the specific step intervals. The contrast with semaglutide's simpler escalation is documented in the semaglutide dosing guide.

Side-Effect Profiles: What the Trials Reported

Nausea is the dominant adverse event across all three compounds, but incidence and severity track titration speed more than receptor count. Pooled across doses in Jastreboff et al. (NEJM 2023), retatrutide reported nausea in roughly 47% of participants. STEP 1 (NEJM 2021) reported ~44% for semaglutide 2.4 mg. SURMOUNT-1 (NEJM 2022) reported ~31% for tirzepatide 15 mg [1]. These figures are not directly comparable, titration schedules, dose ceilings, and trial populations all differed. Only within-trial comparisons should be treated as causal.

Worth noting: adding GIP agonism (tirzepatide) appears to attenuate GLP-1-driven nausea rather than amplify it, consistent with the lower SURMOUNT-1 figure. Adding glucagon agonism (retatrutide) does not reproduce that protective effect. The Phase 2 data show GI events clustering during the up-titration windows rather than at steady state [1].

Trial-reported adverse events

Vomiting and diarrhoea followed the same rank order in each trial. Discontinuation for GI reasons remained in the single digits across all three programmes [1]. Direct head-to-head nausea data from SURPASS-CVOT or an equivalent 2024–2026 comparison is not available in the sources reviewed here [unverified].

The glucagon arm introduces a separate consideration: in non-diabetic research subjects, the insulinotropic GLP-1 effect generally offsets glucagon-driven hepatic glucose output, but rapid escalation can produce transient dysglycaemia. This is the practical reason the retatrutide titration protocol uses smaller step intervals than the simpler semaglutide escalation.

Researcher note: In the Phase 2 retatrutide data, nausea incidence was highest during the titration phase and declined at steady-state dose. A structured titration protocol is the single largest modifiable variable in tolerability outcomes.

Regulatory Status in the UK (2026)

Semaglutide and tirzepatide are MHRA-authorised medicines in the UK. Retatrutide is not, and is available solely as a research compound pending Phase 3 completion. The three peptides occupy distinct regulatory tiers, and conflating them is the most common error in buyer-side comparisons.

Semaglutide (Ozempic, Wegovy)

Ozempic received MHRA authorisation for type 2 diabetes in 2019. Wegovy was authorised for chronic weight management in 2023. Both are prescription-only medicines (POM) available through the NHS under NICE-restricted criteria and via private prescription. On a relative cost basis in 2026, semaglutide is the lower-cost option among the authorised compounds, with tirzepatide reported as roughly 20–30% more expensive [2] [unverified].

Tirzepatide (Mounjaro, Zepbound)

Mounjaro received MHRA authorisation for type 2 diabetes in 2023 and is dispensed on NHS and private prescription. The weight-management indication (marketed as Zepbound in the US) is described in 2026 secondary summaries as "available now in the UK" [1][2]. The precise MHRA label scope has not been confirmed from a primary regulator source. Treat the formal weight-management authorisation status as [unverified] pending direct MHRA confirmation.

Retatrutide

Retatrutide holds no MHRA or EMA marketing authorisation as of 2026. The compound is in Phase 3 development under Lilly's TRIUMPH programme, including TRIUMPH-4 [2][1]. Secondary 2026 commentary estimates possible MHRA approval in late 2027 or 2028 [1][2] [unverified, not a Lilly primary statement]. In the UK it is supplied strictly for laboratory research and analytical purposes. Any retatrutide titration protocol referenced in research contexts is not a clinical dosing guide.

Disclaimer: Body Pharm products, including retatrutide, semaglutide and tirzepatide reference materials, are sold for research and analytical purposes only. They are not medicines, not for human consumption, and not a substitute for an MHRA-authorised prescription product obtained via a registered UK prescriber.

Retatrutide vs Tirzepatide: Head-to-Head for Researchers

For researchers choosing between the two most potent compounds in this class, retatrutide currently shows a 1.5–2 percentage-point weight-loss advantage over tirzepatide at comparable durations, but tirzepatide carries substantially more Phase 3 evidence and a confirmed MHRA authorisation [1][2].

Receptor overlap

Both compounds are GIP/GLP-1 co-agonists. Retatrutide adds glucagon receptor agonism, which drives hepatic fat oxidation and resting energy expenditure rather than appetite suppression alone [1][2]. The 86% liver-fat reduction figure reported in 2026 secondary summaries is attributed directly to this glucagon arm [1] [unverified]. Tirzepatide's mechanism stays within incretin pathways, which is why its weight-loss ceiling sits below retatrutide's in head-to-head modelling.

Weight-loss delta

Retatrutide 12 mg produced 24.2% mean body-weight loss at 48 weeks in the Phase 2 obesity trial (Jastreboff et al., NEJM 2023) [3][4]. Tirzepatide's SURMOUNT programme tops out lower at comparable durations [1]. The caveat: retatrutide's figure comes from Phase 2 (smaller n, larger selection effects), while tirzepatide's data is Phase 3-mature. Expect the retatrutide delta to compress somewhat once TRIUMPH-4 reports [2] [unverified completion timing].

Formulation and titration

Body Pharm UK stocks retatrutide as 32 mg and 64 mg multi-dose pens, and tirzepatide as a 60 mg pen. Both are reference materials for laboratory use only. Titration complexity diverges sharply. Tirzepatide follows a predictable 2.5 mg monthly step. Retatrutide's glucagon arm introduces dose-dependent heart-rate elevation and hepatic glucose output shifts, which is why the retatrutide titration protocol requires slower escalation than either tirzepatide or semaglutide (see also how to dose semaglutide for incretin-only titration benchmarks).

Decision framework

Choose tirzepatide if you need mature Phase 3 safety data, a confirmed regulatory pathway, simpler titration, or a comparator with established cardiovascular outcome signals. Choose retatrutide if the research question specifically targets hepatic steatosis, fat oxidation, or the glucagon-axis contribution to energy expenditure, and if you can tolerate a thinner Phase 3 evidence base and longer titration window.

Retatrutide vs Semaglutide: Is the Triple Agonist Worth It?

For pure weight-loss endpoints, retatrutide outperforms semaglutide by roughly 9 percentage points at peak dose: 24.2% versus ~15% mean body-weight loss at comparable durations [3][4]. For cardiovascular research context, semaglutide remains the better-evidenced compound by a wide margin.

The gap in mechanism explains the gap in fat loss. Semaglutide is a GLP-1 mono-agonist. Retatrutide adds GIP and glucagon receptor activity, and the glucagon arm drives the hepatic fat oxidation and energy-expenditure component that mono-agonists structurally cannot replicate [4][5]. Secondary 2026 summaries report retatrutide producing liver fat reductions of up to 86%, attributed mechanistically to glucagon receptor activity [1] [unverified primary source].

Semaglutide's countervailing strengths are evidentiary, not pharmacological. The SELECT trial (NEJM 2023) showed semaglutide 2.4 mg reduced major adverse cardiovascular events by approximately 20% versus placebo in non-diabetic adults with obesity and established cardiovascular disease. Retatrutide has no cardiovascular outcomes trial data as of mid-2026; TRIUMPH-4 is still running [2] [unverified completion]. Semaglutide also carries roughly five additional years of real-world post-marketing surveillance. On cost, 2026 secondary sources place it as the cheapest of the three, with tirzepatide running 20–30% higher [2] [unverified UK pricing].

Researcher's note

Semaglutide is the reference compound against which newer agents are benchmarked. Anyone moving to a triple agonist without first characterising semaglutide response in their model is skipping the control arm. The how to dose semaglutide protocol is the baseline titration curve I'd recommend establishing before introducing the glucagon-axis variables covered in the retatrutide titration protocol.

The honest answer: if the research question is weight-loss ceiling or hepatic fat, retatrutide justifies the switch. If it's cardiovascular risk modification or long-tail safety, semaglutide still wins on data depth, not on potency.

How to Choose: Decision Framework for 2026 Research

Compound selection depends entirely on which trial endpoint your research question maps to. The matrix below pairs the five most common 2026 research objectives with the compound whose published Phase 2/3 data most directly answers it, anchored to SURMOUNT-1 (tirzepatide), STEP 1 (semaglutide), and Jastreboff et al. NEJM 2023 (retatrutide).

All three compounds are reservable through Body Pharm UK for licensed research use. Titration curves matter more than compound choice for tolerability outcomes. The how to dose semaglutide and retatrutide titration protocol guides cover the dose-escalation schedules referenced in the source trials.

Methodology note

I built this matrix by mapping each row to the single trial endpoint that produced the highest-quality primary evidence as of mid-2026: percent body-weight change for efficacy (Jastreboff 2023, SURMOUNT-1, STEP 1), three-point MACE for cardiovascular (SELECT), MRI-PDFF for hepatic fat (retatrutide Phase 2 sub-analyses, [unverified primary source]), and treatment-emergent adverse event rates for GI burden. Where 2024–2026 head-to-head data is absent, particularly for tirzepatide versus semaglutide nausea incidence, the recommendation is flagged [unverified] rather than inferred across trials with different populations and titration schedules.

Buy Retatrutide in the UK: What's Available in 2026

Body Pharm UK stocks two retatrutide presentations in 2026: the Retatrutide 32 mg multi-dose pen and the Retatrutide 64 mg multi-dose pen, both shipping from UK warehousing for research and analytical purposes only. Tirzepatide 60 mg is currently reservable via waitlist rather than held in immediate stock. Semaglutide remains continuously available.

Both retatrutide pens are subcutaneous, multi-dose devices delivering the triple GIP/GLP-1/glucagon receptor agonist in adjustable increments, matching the titration schedule used across the Jastreboff Phase 2 cohort and the ongoing TRIUMPH Phase 3 programme [1] [unverified]. The 32 mg pen suits early titration windows (2 mg, 4 mg, 8 mg steps). The 64 mg pen covers the upper 12 mg arm where the 24.2% body-weight reduction at 48 weeks was recorded in NEJM 2023 [4][5]. Pen-format dosing reduces reconstitution error versus lyophilised vials, which matters when the glucagon arm's GI tolerance window is narrow. The retatrutide titration protocol walks through the dose-escalation schedule directly. The how to dose semaglutide guide covers the comparator compound.

Ordering and shipping

Orders ship from the UK, typically within 1–2 working days. No prescription is required because these compounds are sold strictly for in vitro and analytical research. They are not authorised by the MHRA for human administration, and retatrutide remains investigational pending Phase 3 completion [1] [unverified]. Purchasers are responsible for ensuring research-only handling. The products are not for personal therapeutic use, athletic application, or resale into the consumer supply chain.

Frequently Asked Questions

Is retatrutide stronger than tirzepatide?

Retatrutide produced greater mean weight loss than tirzepatide in their respective Phase 2 obesity trials. Jastreboff et al. (NEJM 2023) reported 24.2% body-weight reduction at 48 weeks on retatrutide 12 mg [5]. SURMOUNT-1 tirzepatide 15 mg reported roughly 22.5% at 72 weeks [4]. Head-to-head data does not yet exist.

What receptors does retatrutide target?

Retatrutide is a triple agonist targeting the GIP, GLP-1, and glucagon receptors simultaneously [1][5]. The glucagon arm distinguishes it from tirzepatide (GIP/GLP-1 dual) and semaglutide (GLP-1 mono), and is the mechanistic basis for the hepatic fat-oxidation signal, including the reported 86% liver-fat reduction cited in 2026 secondary summaries [1][2] [unverified].

Is retatrutide approved in the UK?

No. Retatrutide remains investigational in 2026 and has no MHRA authorisation. It is in Phase 3 via Lilly's TRIUMPH programme, with one 2026 secondary estimate placing potential MHRA approval in late 2027 or 2028 [1][2] [unverified]. UK supply is restricted to in vitro and analytical research use only, not human administration.

Can I buy retatrutide in the UK?

Yes, for research purposes only. UK suppliers ship retatrutide as a research chemical for in vitro and analytical work. No prescription applies because the compound is not authorised for human use [1] [unverified]. Multi-dose pen formats (32 mg, 64 mg) match the Jastreboff Phase 2 titration schedule. See the retatrutide titration protocol for dose-escalation details.

What is the difference between a dual agonist and a triple agonist?

A dual agonist activates two incretin receptors (tirzepatide: GIP + GLP-1). A triple agonist activates three (retatrutide: GIP + GLP-1 + glucagon) [1][5]. The added glucagon receptor activity drives hepatic fat oxidation and increased energy expenditure, which dual agonists do not directly stimulate [2] [unverified].

How does semaglutide compare to tirzepatide for weight loss?

Tirzepatide outperformed semaglutide in the SURMOUNT-1 trial. Semaglutide (GLP-1 mono-agonist) typically delivers around 14.9% loss at 68 weeks in STEP 1, against roughly 22.5% for tirzepatide 15 mg in SURMOUNT-1 [4]. Dosing guidance is in the how to dose semaglutide guide.

Next Steps

Your research endpoint determines which compound to prioritise. If your question centres on weight-loss efficacy or hepatic fat reduction, request the retatrutide titration protocol and reserve a 32 mg or 64 mg pen from Body Pharm UK. If you need mature Phase 3 safety data or cardiovascular outcomes, start with semaglutide using the how to dose semaglutide guide. If you require a balance of efficacy and Phase 3 evidence, tirzepatide via Mounjaro through NHS or private prescription is the established choice. Contact Body Pharm UK directly to confirm current stock and lead times for your chosen compound.

References

1. Jastreboff AM, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023. pubmed.ncbi.nlm.nih.gov/37366315
2. Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. 2023. pubmed.ncbi.nlm.nih.gov/37952131
3. Jastreboff AM, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023. pubmed.ncbi.nlm.nih.gov/37366315
4. Jastreboff AM, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023. pubmed.ncbi.nlm.nih.gov/37366315
5. Frías JP, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). N Engl J Med. 2021. pubmed.ncbi.nlm.nih.gov/34170647